However, several studies suggested that high RARRES1 expression is significantly correlated with poorer clinical outcomes in patients with clear cell renal cell carcinoma and inflammatory breast cancers (Wang et al., 2013; Geng et al., 2022). This evidence concerns the gene RARRES1 and inflammatory breast carcinoma.